Press Release

Press Release...

URGENT

AS PER THE FOLLOWING PRESS RELEASES, EFFECTIVE JANUARY 5, 2001 INDIGO MEDICAL, INC WILL NO LONGER BE DISTRIBUTING THERAGENICS' PRODUCTS.

PLEASE CONTACT PROSTATE SERVICES OF AMERICA (PSA) FOR YOUR TheraSeed® NEEDS. PSA IS THE PREMIER NATIONWIDE SUPPLIER OF COMPLETE SOLUTIONS FOR PROSTATE BRACHYTHERAPY, INCLUDING ALL NECESSARY EQUIPMENT, RADIOACTIVE SOURCES AND RELATED SERVICES.

Please Contact Kathy Youney At:
PROSTATE SERVICES OF AMERICA, INC.
2655 North Ocean Drive - Suite 405
Singer Island, Florida 33404

PHONE: 1-877-438-4125
FAX: 1-561-842-6660
E-MAIL: kathy@prostateservices.com
http://www.prostateservices.com

November 27, 2000

Theragenics Announces TheraSeed® Distribution Agreement with Prostate Services of America

Buford Ga. (November 27, 2000) - Theragenics Corporation (NYSE: TGX), today announced that it has signed a five-year agreement with Prostate Services of America, Inc. (PSA) for the distribution of TheraSeed®. Under the terms of the non-exclusive agreement, PSA will be permitted to distribute TheraSeed® immediately in the U.S., Canada and Puerto Rico for the treatment of prostate cancer and other solid localized cancerous tumors.

"I am delighted that TheraSeed® will now be available through Prostate Services of America and its full service approach to brachytherapy," said M. Christine Jacobs, chairman, president and CEO of Theragenics Corporation. "It is gratifying to know that TheraSeed® is being recognized as an industry leader in the treatment and cure of prostate cancer."

The agreement represents another significant and strategic step for Theragenics' previously stated plan to make TheraSeed® available through a variety of non-exclusive distribution channels. This plan includes continued support of the TheraSeed® brand as well as clinical studies and in-field technical support for TheraSeed® and its uses.

"We are extremely pleased to be able to market TheraSeed® to our customers. Now we can offer physicians a complete set of tools for prostate implantation, all from one trusted source. We are excited about establishing a relationship with Theragenics, the market leader in radioactive palladium seeds, and we are confident that this will benefit both of our companies," said Greg Wiita, Vice President of Marketing and Sales for PSA.

Theragenics Corporation, based in Buford, Ga., is the manufacturer of TheraSeed®; a rice-sized device used in the treatment of localized prostate cancer with a one-time, minimally invasive procedure. Theragenics is the world's largest producer of palladium-103 and is also involved in research and development utilizing palladium-103 for the treatment of restenosis, macular degeneration and other diseases and research and development centered around other isotopes and their usage. For additional information of the company, call Theragenics' Investor Relations Department at 800-998-8479. The Company's common stock is traded on the New York Stock Exchange under the symbol TGX.

Based in Singer Island, Florida, Prostate Services of America, Inc. is the premier nationwide supplier of complete solutions for prostate brachytherapy, including all the necessary equipment, radioactive sources, and related services.

THERAGENICS ANNOUNCES EARLY TERMINATION OF INDIGO DISTRIBUTION PACT

Buford, Ga. (December 6, 2000), Theragenics Corporation (NYSE: TGX), announced today that the Company and Indigo Medical, Inc., a Johnson & Johnson company, have agreed to accelerate the termination of Indigo's distribution rights for TheraSeed® effective close of business January 5, 2001. Theragenics had previously announced that Indigo had exercised its right to terminate its distribution of TheraSeed® under the existing contract, which would have been effective August 10, 2001. Letters are already in the mail to TheraSeed® customers explaining the transition.

"We are pleased with Indigo's decision to accelerate their exit from the agreement. We believe this is prudent and represents a positive move for both organizations. This gives Theragenics the opportunity to accelerate its efforts to restructure its distribution channels. Going forward, TheraSeed® will be available through the group of fine distributors we have assembled, as well as directly from the Company to the extent existing customers prefer," stated M. Christine Jacobs, Theragenics' chairman, president and CEO.

As a result of the accelerated agreement, Theragenics has agreed to waive any capital carrying costs that Indigo would otherwise be obligated to pay. These carrying costs are calculated by applying Theragenics' bank-borrowing rate to the cost of cyclotrons already purchased but not being used to full capacity to support product sales. Since this calculation is dependent on actual product sales, the actual amount of carrying costs waived cannot be determined.

Theragenics Corporation, based in Buford, Ga., is the manufacturer of TheraSeed®; a rice-sized device used in the treatment of localized prostate cancer with a one-time, minimally invasive procedure. Theragenics is the world's largest producer of palladium-103 and is also involved in research and development utilizing palladium-103 for the treatment of restenosis, macular degeneration and other diseases and research and development centered around other isotopes and their usage. For additional information on the company, call Theragenics' Investor Relations Department at 1-800-998-8749. The Company's common stock is traded on the New York Stock Exchange under the symbol TGX.

Except for historical information contained herein, the matters discussed in the press release are forward looking statements, including: Theragenics' restructuring of distribution channels of Indigo TheraSeed® sales, assistance from Indigo during its transition out of TheraSeed® sales, and acceleration of termination being a prudent and positive move. Actual results may differ materially for a variety of factors, including, among other things, Theragenics' execution of marketing plans, competitors' execution of their own marketing strategies, TheraSeed's® distributors' success in converting Indigo's customer base to their accounts, reimbursement changes, price competition, the state of the general healthcare industry as a whole, Indigo resources and cooperation during the transition phase and other factors set forth from time to time in the Company's Securities and Exchange Commission filings.

For any additional information needed, contact us below:

Prostate Services of America, Inc.
2655 N. Ocean Drive Suite 405 ~ Singer Island, Fl. 33404
Toll free: 1-877-GET-I-125 0r 561-842-8900
Fax: 561-842-6660
E-mail: Info@prostateservices.com